Accelerating Formulation for Antibody-Based Therapeutics
Accelerating Formulation for Antibody-Based Therapeutics
In the “Quality by Design” approach to mAb-based therapeutics development, characterizing protein stability helps preserve structure and function.
Written byThe Scientist Creative Services Team
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
